



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Hui-jie Leng,
✉ lenghj@bjmu.edu.cn
Yan Niu,
✉ yanniu@bjmu.edu.cn
Mo-pei Wang,
✉ wangmopei@126.com

RECEIVED 26 June 2023
ACCEPTED 04 July 2023
PUBLISHED 26 July 2023

CITATION

Li C-h, Lü Z-r, Zhao Z-d, Wang X-y,
Leng H-j, Niu Y and Wang M-p (2023),
Corrigendum: Nitazoxanide, an
antiprotozoal drug, reduces bone loss in
ovariectomized mice by inhibition of
RANKL-induced osteoclastogenesis.
Front. Pharmacol. 14:1247393.
doi: 10.3389/fphar.2023.1247393

COPYRIGHT

© 2023 Li, Lü, Zhao, Wang, Leng, Niu and
Wang. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis

Chang-hong Li^{1,2}, Zi-rui Lü³, Zhen-da Zhao^{2,4}, Xin-yu Wang¹,
Hui-jie Leng^{2,5*}, Yan Niu^{3*} and Mo-pei Wang^{2,6*}

¹Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ²Osteoporosis and Bone Metabolic Diseases Center, Peking University Third Hospital, Beijing, China, ³Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China, ⁴Department of Orthopaedics, Peking University Third Hospital, Beijing, China, ⁵Beijing Key Laboratory of Spinal Disease Research, Beijing, China, ⁶Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing, China

KEYWORDS

nitazoxanide, stat3, osteoclastogenesis, Nfatc1, osteoporosis

A Corrigendum on

[Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis](#)

by Li C-h, Lü Z-r, Zhao Z-d, Wang X-y, Leng H-j, Niu Y and Wang M-p (2021). *Front. Pharmacol.* 12: 781640. doi: 10.3389/fphar.2021.781640

In the published article, there was an error in the **Funding** statement. The original statement read: “This work was supported by National Natural Science Foundation of China (No. 81501387, No. 12172011, No. 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02) and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).” This statement should be corrected as follows:

Funding

This work was supported by Scientific Research Foundation of Returned Scholars of Peking University Third Hospital (LXHG2018003), National Natural Science Foundation of China (Nos 81501387, 12172011, and 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02), and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.